U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07717814) titled 'A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity' on July 16.

Brief Summary: The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered as a single subcutaneous (SC) dose using a liquid drug product in vial compared to a frozen liquid drug product in vial in participants living with overweight or obesity.

Study Start Date: Nov. 26, 2024

Study Type: INTERVENTIONAL

Condition: Overweight and Obesity

Intervention: DRUG: AMG 133 (frozen liquid)

AMG 133 will be administered as a SC injection.

DRUG: AMG 133 (liquid)

AMG 133 will be administered as a SC...